Cargando…

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?

We evaluated whether low-density lipoprotein cholesterol (LDL-C) levels in familial hypercholesterolemia patients on triple lipid-lowering therapy would remain below intensification threshold values after withdrawal of ezetimibe. We included 13 heterozygous familial hypercholesterolemia patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hang, Shyann, Lazarte, Julieta, Hegele, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039577/ https://www.ncbi.nlm.nih.gov/pubmed/35495867 http://dx.doi.org/10.1016/j.cjco.2021.12.005

Ejemplares similares

Liver Injury Associated With Ezetimibe Monotherapy
por: Kanagalingam, Tharsan, et al.
Publicado: (2020)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
por: Huang, Chin-Chou, et al.
Publicado: (2019)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
por: Hamilton-Craig, Ian, et al.
Publicado: (2010)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Deprescription in Advanced Cancer Patients
por: Gonçalves, Ferraz
Publicado: (2018)

Deprescription: The prescription metabolism
por: Sivagnanam, Gurusamy
Publicado: (2016)

Deprescription in Palliative Care
por: Cabrera, Joana A, et al.
Publicado: (2023)

Short-term evolocumab-induced tendon xanthomas regression in an elderly patient with homozygous familial hypercholesterolemia
por: Cicero, Arrigo F. G., et al.
Publicado: (2022)

Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

Improving Pharmacists’ Targeting of Patients for Medication Review and Deprescription
por: Marvin, Vanessa, et al.
Publicado: (2018)

An Untargeted Lipidomic Analysis Reveals Depletion of Several Phospholipid Classes in Patients with Familial Hypercholesterolemia on Treatment with Evolocumab
por: Anesi, Andrea, et al.
Publicado: (2021)

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial
por: Koba, Shinji, et al.
Publicado: (2020)

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
por: Ge, Xiaoyue, et al.
Publicado: (2021)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
por: Kuchimanchi, Mita, et al.
Publicado: (2018)

The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia
por: NODARI, SAVINA, et al.
Publicado: (2007)

Lamin A/C missense variants: from discovery to functional validation
por: Lazarte, Julieta, et al.
Publicado: (2021)

Can one overcome “unhealthy genes”?
por: Lazarte, Julieta, et al.
Publicado: (2019)

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
por: Pirillo, Angela, et al.
Publicado: (2022)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Sitosterolemia Exhibiting Severe Hypercholesterolemia with Tendon Xanthomas Due to Compound Heterozygous ABCG5 Gene Mutations Treated with Ezetimibe and Alirocumab
por: Tanaka, Hiroki, et al.
Publicado: (2020)

Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia
por: Hang, Shyann M.T., et al.
Publicado: (2023)

The Barriers to Deprescription in Older Patients: A Survey of Spanish Clinicians
por: Mejías-Trueba, Marta, et al.
Publicado: (2023)

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
por: Bays, Harold E., et al.
Publicado: (2021)

Evidence for deprescription in primary care through an umbrella review
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2020)

Homozygous familial hypercholesterolemia
por: Parihar, Ravi Kumar, et al.
Publicado: (2012)

Effect of fixed‐dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS‐ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)
por: Kim, Kyung‐Jin, et al.
Publicado: (2016)

Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis
por: Liang, Di, et al.
Publicado: (2022)

A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab
por: Inoue, Ikuo, et al.
Publicado: (2020)

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
por: Koren, Michael J., et al.
Publicado: (2020)

Familial hypercholesterolemia: The skin speaks
por: Johnson, Johns T., et al.
Publicado: (2020)

Ezetimibe: An Unusual Suspect in Angioedema
por: Lu, Tiffany, et al.
Publicado: (2020)

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
por: Dent, Ricardo, et al.
Publicado: (2016)

The influence of ezetimibe on classical and alternative activation pathways of monocytes/macrophages isolated from patients with hypercholesterolemia
por: Suchy, Dariusz, et al.
Publicado: (2014)

Effects of Evolocumab on Carotid Intima-Media Thickness and Clinical Parameters in Patients Taking a Statin
por: Hirai, Keiji, et al.
Publicado: (2020)

Beliefs and attitudes about deprescription in older HIV-infected patients: ICARD Project
por: Giménez, Reyes Serrano, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ihsd8mfn3c3cm9sl0et70lunj7